Estimated prevalence of Ig isotypes and IgG subclasses of FVIII-binding antibodies found in healthy individuals and in different cohorts of hemophilia A patients
| Study cohort . | Sample size . | IgG1, %* . | IgG2, %* . | IgG3, %* . | IgG4, %* . | IgA, %* . | IgM, %* . |
|---|---|---|---|---|---|---|---|
| Healthy | 600 | 6 | 1 | 6 | 0 | 6 | 1 |
| Hemophilia A without inhibitor (HA-noINH) | 77 | 19 | 1 | 13 | 0 | 4 | 3 |
| Hemophilia A after successful ITI (HA-ITI) | 23 | 30 | 9 | 4 | 0 | 0 | 0 |
| Hemophilia A with inhibitor (HA-INH) | 20 | 95 | 35 | 25 | 95 | 10 | 5 |
| Acquired hemophilia A (Acqu-HA) | 9 | 100 | 67 | 22 | 100 | 11 | 11 |
| Study cohort . | Sample size . | IgG1, %* . | IgG2, %* . | IgG3, %* . | IgG4, %* . | IgA, %* . | IgM, %* . |
|---|---|---|---|---|---|---|---|
| Healthy | 600 | 6 | 1 | 6 | 0 | 6 | 1 |
| Hemophilia A without inhibitor (HA-noINH) | 77 | 19 | 1 | 13 | 0 | 4 | 3 |
| Hemophilia A after successful ITI (HA-ITI) | 23 | 30 | 9 | 4 | 0 | 0 | 0 |
| Hemophilia A with inhibitor (HA-INH) | 20 | 95 | 35 | 25 | 95 | 10 | 5 |
| Acquired hemophilia A (Acqu-HA) | 9 | 100 | 67 | 22 | 100 | 11 | 11 |
FVIII indicates factor VIII; and ITI, immune tolerance induction therapy.
Many samples contained different populations of antibodies that were individually assessed for prevalence. Therefore, the sum of the prevalence of the individual isotypes and subclasses may be > 100%.